Hepatitis E virus (HEV) is an RNA virus that is an important cause of both acute and chronic hepatitis worldwide. To date, there are eight HEV genotypes that can infect mammals. HEV-1 and HEV-2 infect exclusively humans, while HEV-3 and HEV-4 infect humans and various animals, mainly pigs and deer. Additionally, two new genotypes (HEV-5 and HEV-6) infect mainly wild boar. Recently, newly discovered genotypes HEV-7 and HEV-8 were found to infect camels and possibly humans. Nevertheless, the epidemiological distribution of HEV-7 is not well established. HEV-8 is another newly discovered genotype that was identified in 2016 in Chinese Bactrian camels. Although faecal-oral transmission is the most common route of HEV transmission, HEV can be vertically transmitted from infected mothers to their fetuses. HEV may also spread by zoonotic transmission from infected animals to humans and through person-to-person contact. Nowadays, since the number of reported cases linked to blood donations is increasing annually, HEV is recognized as a transfusion-transmitted virus. Laboratory diagnostic techniques vary in their specificity and sensitivity for HEV detection. Direct techniques allow for detection of the viral proteins, antigens and viral nucleic acid, while HEV-specific IgG and IgM antibodies can help establish a diagnosis in acute and chronic infections. In this review, we will discuss recent technologies in the laboratory diagnosis of HEV, including serological and molecular methods to assess the specificity and sensitivity of currently available HEV commercial assays.
INTRODUCTION
Hepatitis is a global health issue that results in injury and destruction of hepatocytes, resulting in acute and chronic liver disease. Although hepatitis is commonly caused by viral infections, other non-infectious causes such as autoimmune diseases, toxins and drugs can also lead to hepatitis [1, 2] . To date, there are five main types of viral hepatitis, referred to as hepatitis A-E. HEV is the aetiological agent of hepatitis E infection and one of the leading causes of acute and chronic liver inflammation. It is a small, non-enveloped, single-stranded, positive-sense RNA virus [3] . HEV is a member of the Hepeviridae family, genus Orthohepevirus [4] . Until recently, eight genotypes of HEV (HEV-1 to HEV-8) have been shown to infect mammals and are classified based on variations in open reading frame 2 (ORF2); all belong to one serotype [5, 6] . HEV-1 and HEV-2 are restricted to humans and account for many recurrent outbreaks in endemic areas of Africa, including Egypt [7, 8] , Sudan [9] and Uganda [10, 11] ; America, such as in Mexico [12] ; and Asia, such as China [13] and India [14] . HEV-3 and HEV-4 are known to infect animals, but can also be transmitted to humans. Geographically, HEV-3 is responsible for sporadic cases worldwide, including Europe and USA [15] . HEV-4 is predominant in Southeast Asia [16] . HEV-5 and HEV-6 infect mainly wild boar [17] . HEV-7 is a newly discovered HEV genotype and was identified in the United Arab Emirates (UAE) [18] . It is thought that HEV-7 infects primarily dromedary camels, as it was first discovered in camel faeces. However, the same viral sequence was isolated from the faeces of an acute hepatitis patient, suggesting that the virus can infect both human and camels [19] . Similarly, HEV-8 was identified in Bactrian camels in China, but to date HEV-8 viral sequences have not been detected in humans [20] .
In more than 90 % of cases, HEV infection is asymptomatic and self-limiting. However, in other cases, HEV presents with typical symptoms of acute hepatitis such as jaundice, nausea, vomiting and hepatosplenomegaly as well as elevated liver transaminases [21] . Additionally, chronic HEV infection, which is mainly caused by HEV-3, has been found in patients with underlying medical conditions including chronic liver diseases and haematological malignancies [22] . Cirrhosis linked to chronic HEV-3 infection post-transplant is seen as an important treatable condition that requires monitoring of blood specimens to determine the response to therapy [23] . HEV infection can also be very severe when compared to other types of viral hepatitis during pregnancy [24] . Pregnant women, especially in the third trimester, are at higher risk of severe HEV infection associated with acute liver failure, birth complications and a significant mortality rate [3, 25] . According to the World Health Organization (WHO), the mortality rate of HEV is 1-2 % worldwide, resulting in approximately 56 600 deaths per year [1] . However, the mortality rate increases to 30 % in pregnant women and to about 75 % in patients with underlying liver conditions [22] . In pregnant women, HEV-1 and HEV-2 are likely to cause serious medical complications including liver failure, increased risk of miscarriage and premature delivery. To date, there are no data suggesting that HEV-3 is associated with serious consequences during pregnancy [26, 27] .
HEV is mainly transmitted by the faecal-oral route, as well as by zoonotic transmission through direct contact with animals [1] . It can also be transmitted through consumption of contaminated food and vertically from mothers to their fetuses [1] . Since 2004, occasional transmission of HEV infection through blood transfusion has been reported in several countries including Japan, the UK, France, Denmark and Saudi Arabia [28] [29] [30] [31] [32] [33] [34] . The threat posed by HEV-3 transmission from both blood products and organ donations has resulted in the introduction of universal screening in the UK to lower the risk of transmission [35] . HEV is a blood transfusion-transmissible virus, and it is considered a potential risk especially for pregnant women, patients with liver diseases and immunocompromised patients.
For laboratory diagnosis, detection of HEV antibodies provides a good understanding of HEV infection and aids in diagnosis. Nevertheless, several studies have shown that serological tests do not provide enough confirmatory evidence as to whether blood products contain HEV RNA [36, 37] . Even though serological assays are more reliable in terms of cost and simplicity, their diagnostic sensitivity and specificity in regard to HEV detection are relatively low. Accordingly, HEV RNA detection by molecular assay remains the gold standard to confirm viraemia [38, 39] . Despite these facts, screening of blood products prior to blood transfusion, especially in low income-endemic areas, for the presence of HEV RNA remains difficult to achieve [23, 39] . First, many studies have shown that the infection rate of HEV RNA among blood donors is very low in some countries (e.g. 0.04 % in England). Second, HEV does not cause serious infection or disease, but mainly affects highrisk populations including pregnant women, patients with liver disease and immunocompromised patients. Third, and probably most important, performing the test for RNA detection is very expensive and laborious. Accordingly, recent studies suggest that conducting more scientific research, focusing on seroprevalence studies, is crucial to verify whether additional methods for HEV RNA detection in blood banks are necessary [36] .
HEV VIRAL CHARACTERISTICS
HEV belongs to the family of Hepeviridae and it is the only member of the genus Orthohepevirus. HEV is a small, nonenveloped RNA virus of 27-34 nm diameter. Its genome is a positive-sense, single-stranded, linear RNA with a genomic length of approximately 7.2 kb [16] . Its genome has a short 5¢-untranslated region (UTR) methylguanine-caped, three open reading frames (ORFs) and a polyadenylated 3¢-UTR (Fig. 1) . ORF1 has several conserved domains, of which some code for non-structural proteins required for viral Fig. 1 . A schematic diagram of HEV genome. Its genome is a positive-sense, single-stranded, linear RNA with a genomic length of approximately 7.2 kb, with a short 5¢-untranslated region (UTR) methylguanine-caped, three open reading frames (ORFs) and a polyadenylated 3¢-UTR; 5¢ and 3¢ non-coding regions (5¢NCR and 3¢NCR). ORF1 codes for polyprotein that is processed into 7-methylguanosine cap (cap), methyltransferase (METH), Y-domain (Yd), papain-like cysteine protease (PCP), a proline-rich region (PRR) consisting of a hyper-variable region (HVR), X-domain (Xd), helicase (Hel) and RNA-dependent RNA polymerase (RdRp). ORF2 codes for capsid protein and structural protein 2 (SP2). ORF3 codes for multifactorial protein (MP), which is further processed into putative capsid protein (PCsP). A junctional region (JR) connects ORF1 and ORF2/ORF3, containing a stem loop sequence and two cis-reactive element (CRE). At the 3¢ end is the poly-adenosine tail sequence (Poly-AAA). Adapted from molecular biology and replication of HEV and NCBI maps [16, 128] .
replication: a putative methyltransferase (MT), papain-like cysteine protease (PCP), a helicase (Hel) and RNA-dependent RNA polymerase (RdRp). ORF2 encodes for viral capsid protein, while ORF3 encodes for a small, cytoskeleton-associated proprotein [40] .
HEV replication within the host is not fully understood, since it does not have a specific potent cell line for culture. However, HEV can grow in animal model systems, such as pig-and chicken-based models, that will help in understanding HEV replication and pathogenicity [41, 42] . HEV capsid protein is believed to be essential for binding to a cellular receptor to initiate virus entry and replication [16] . According to in vitro experiments, capsid protein binds to the heat shock cognate protein 70 on the cell surface [43] . However, no specific cellular receptor has yet been discovered for HEV entry. After the virus enters the target cell, the HEV genome is uncoated and released into the cytoplasm by an as yet unknown mechanism. Then, HEV RNA is translated into non-structural proteins. The viral RNAdependent RNA polymerase (RdRp) synthesizes a negativesense intermediate RNA, which in turn serves as a template to produce positive-sense progeny viral RNA as well as subgenomic RNA. This sub-genomic RNA is translated into ORF2 and ORF3 proteins. ORF2 capsid protein packages the genomic RNA into new virions, which are transported to the cell membrane and ultimately released outside the infected cell [16] .
LABORATORY DIAGNOSIS OF HEV
HEV clinical manifestations and biochemical tests are unable to confirm a diagnosis of HEV infection alone, but are helpful in recognizing the onset and stage of infection. A diagnosis of HEV requires optimally a combination of both molecular and serological techniques to both confirm infection and monitor the response to treatment in chronically infected patients. There are several serological and molecular techniques for HEV detection that can be used to detect viral proteins and/or genome.
Serological methods
Production of antigen assays Viral antigens are present in blood and liver during the early phase of acute hepatitis E infection, and may persist for longer periods in chronic HEV infections. Detecting viral antigens is one of the direct methods for revealing HEV viraemia, using double-antibody sandwich enzyme immunoassay (EIA) techniques [44] . The antigens used to detect HEV are derived from ORF2, which codes for capsid protein [45] . Despite the fact that ORF3 antigens do not code for capsid protein, they are used to detect HEV [16] . ORF3 antigens are detectable in serum during the acute course of infection and cell culture suspension [46] . There are multiple combinations of the sandwich enzyme-linked immunosorbent assay (ELISA) that can be used. For instance, monoclonal or polyclonal antibodies are used to coat the micro-wells to capture HEV antigens. Both types of antibodies are also used to detect antigens after the capturing step, and both are equivalent in efficiency, although polyclonal antibodies with the biotin amplification system (LAB) display a better positive ratio [45] .
A study performed on monkeys revealed that HEV antigens were detectable in faeces 1 week post infection and persisted for a period of 6 weeks [45] . This window was the closest to HEV RNA compared to other markers in which HEV RNA was detectable from 1 week post infection until around 8 weeks (Fig. 2) . HEV antigens in serum also appeared after 1 week and lasted for 7 weeks post infection [47] . Antigens in urine have a higher titre when compared to serum and faeces [48] . When comparing HEV antigen assays to RNA, HEV antigen has a good concordance and correlation to HEV RNA whereas that of HEV RNA and HEV IgM is poor [38, 45, 49] . RT-PCR is also more sensitive than HEV antigen assays [38, 49] . However, RT-PCR can be affected by different genotypes, due to variation in sequence, while HEV antigen assays are more likely to tolerate such genotype sequence variations [45] .
HEV antigens are inversely related to the concentration of HEV IgM antibodies in blood. When serum containing HEV antibody was mixed with cell culture supernatants infected with HEV, the signal to cut-off ratio (S/CO) of antigens assays was reduced in comparison to the control group [38] . Furthermore, in immunocompromised patients, the S/CO ratio of antigen assays was higher than that seen in immunocompetent individuals, linked to decreased production of HEV antibody [38, 49] . Viral antigen detection during replication of HEV is more likely to be detectable in chronic hepatitis E infection, even in the presence of HEV antibodies. Therefore, antigen and HEV antibody assays can be used to confirm chronic hepatitis E infection to initiate antiviral therapy [39] . HEV ELISA antigen assays have excellent specificity, as they do not cross-react with other hepatitis viruses like hepatitis A, B, C or herpesviruses [49] . However, sensitivity is a major concern with HEV ELISA antigens assays, since it ranges from 40 to 91 % [38] . According to the literature, Wantai assay (ELISA) for HEV IgG detection is one of the most commonly used commercial kits. Based on our research experience and published reports, Wantai HEV IgG assay has the highest sensitivity and specificity, thus being more reliable in estimating the seropositivity rates of HEV antibodies [50] [51] [52] [53] [54] [55] [56] [57] [58] . In the absence of definitive molecular techniques, detecting HEV antigen and/or antibodies by ELISA is a valuable alternative assay in the early phase of HEV infection [38, 39, 45] .
Indirect detection of HEV antibodies
HEV infection is diagnosed indirectly by the detection of HEV antibody, HEV IgM and IgG, produced as part of a humoral immune response to virus exposure. During acute HEV infection, HEV IgM become detectable in serum with the onset of symptoms, suggesting recent infection and that IgM production persists for several months [59] . In contrast, HEV IgG represents past or chronic infection and follows IgM production, persisting longer in serum than IgM antibody (Fig. 2) . Some studies suggest that IgG antibodies remain for years after recovery, although the exact duration is not yet determined [59] . Additionally, IgA immunoglobulin is also produced against HEV infection in line with the IgM titre (Fig. 2) . Studies reported that IgA detection aids in the diagnosis of acute HEV infection, along with IgM or in the case of negative HEV IgM results [60] [61] [62] . Noteworthy, although HEV has several genotypes, they all elicit very similar immune responses [6] .
In clinical settings, ELISA is used routinely to detect HEV antibody, in addition to rapid immune-chromatographic tests. There are several serological assays available to detect HEV antibody, and these mainly differ in the solid phase coating, sample dilution, incubation time and cutoff line used to interpret the results. There are several commercial and in-house ELISAs that utilize the recombinant proteins or synthetic peptides as antigens bound to the solid phase of the assay (Table 1) . These antigens represent the immune-dominant epitopes from ORF2 and/or ORF3, produced to be captured by HEV antibody in the patient's serum [21] . Additionally, some ELISAs use artificial mosaic proteins containing several short segments of HEV proteins with antigenic epitopes [63] . However, since recombinant antigens exhibit the conformational epitopes better than short peptides, they have shown higher sensitivity levels [21, 64] .
These serological assays are relatively easy to perform and less expensive than molecular tests, yet they vary in performance characteristics with regard to sensitivity and specificity. Based on many studies, the available commercial ELISAs reveal obvious discrepancies in the results, despite the use of identical samples [53] [54] [55] [56] [64] [65] [66] . Also, serological analysis of HEV infection can be very difficult given that the results of these ELISAs are inconsistent and inconclusive due to cross-reactivity with other viruses [67] . Although immunoblot assays are also designed for detecting HEV antibodies, they suffer from poor performance [60] . A graph illustrating the pathogenic events throughout the course of HEV infection. HEV RNA can be detected very early in the acute course of infection, and starts to decline in serum to undetectable levels wat 5-6 weeks post infection. Subsequently, it starts to appear in the stool after approximately 2 weeks post infection. RNA is detectable only during the acute phase of infection, making it more specific to acute infection and superior to serological detection of antibodies, which are also detected during both acute and convalescent periods. The first HEV antibody produced is IgM, and it may persist until 6 months post infection. IgA is produced after IgM and is detectable about 1 month post infection. Hence, the detection of IgM and IgA represents an acute HEV infection. However, in the chronic infection phase, IgG becomes detectable and persists for longer than IgM and IgA. In addition, alanine aminotransferase (ALT), a liver marker enzyme, can be used as a useful tool in the diagnosis of HEV infection. Immunoblot assays differ from ELISAs in having nitrocellulose strips coated with purified recombinant HEV antigens: O2N, O2C and O2M capsid proteins, and O3 protein from ORF3. O2N is the N-terminal part of ORF2 protein, while O2C and O2M represent the C-terminal part and middle part of ORF2, respectively (adapted from product insert sheet of recomLine HEV IgG/IgM Mikrogen kit) [68] .
Immunoblot assays involve a lengthy procedure and long incubation periods with the patient's serum and antibody conjugate. Moreover, the interpretation of immunoblot results depends on the development of visible coloured bands on the test strips, with different colour intensity based on the quantity of the attached antibodies. Mikrogen Diagnostik is the only company that manufactures immunoblot assays for HEV IgM and IgG detection. However, the newly introduced immune-chromatographic assay for rapid detection of HEV IgM showed good performance with relatively high sensitivity and specificity [69] [70] [71] . The rapid IgM assay yields results within a few minutes and is relatively easy to use as an alternative diagnostic tool, especially in resourcelimited areas. This IgM assay yields results that are very consistent with those provided by reference ELISA assays [69] . Two companies design this IgM assay: Wantai and MP diagnostics. The assay is manufactured as a small card that has a nitrocellulose membrane with immobilized monoclonal anti-human IgM antibodies at the test zone, while HEV antibodies are bound at the control zone. When a sample is added, it will migrate by capillary diffusion action, and HEV IgM, if present in the sample, will bind to colloidal gold conjugated to HEV antigens and form particles. These particles will continue to migrate until the test zone, where they are captured by anti-human IgM antibodies. This reaction will generate a visible red line. If HEV IgM is not present in the sample, no red line is formed in the test zone and the particles will continue to migrate until they reach the control zone. Thereafter, they will be captured by antibodies to HEV and form a red line, indicating the validity of the test. In some studies, IgM immunochromatographic assays demonstrated higher sensitivities than certain ELISA-based assays [72, 73, unpublished data] . It is important to mention that there is no single Food and Drug Administration (FDA)-approved serological assay that can be used for the clinical diagnosis of HEV. The available assays can only aid in the diagnosis of HEV infection, and can be used in epidemiological studies (Table 1) . Based on several studies performed to determine HEV seroprevalence, it was noted that analyses performed on acute hepatitis samples using HEV IgM commercial assays revealed variation in the diagnostic performance characteristics of such commercial assays [74] [75] [76] . Importantly, for immunocompromised patients, detecting HEV antibody could fail in establishing an accurate diagnosis of HEV due to delayed seroconversion. Therefore confirmation of HEV infection increasingly relies on molecular diagnostic methods.
Molecular methods
At present, HEV infection is commonly diagnosed with serological markers in blood, but these have recognized limitations [77] . Although detection of HEV antibody provides an understanding of HEV seroprevalence and current and past infection, several studies have shown they lack sensitivity for screening for persistent HEV RNA in donor blood products [36, 78] . Unlike HEV RNA, HEV IgM may not reach detectable levels in the early stages of infection. HEV IgM is also detectable during the convalescent period (3-5 months post infection) [79, 80] . Hence, relying on antibody detection only could lead to misdiagnosis of acute HEV in many infected cases. Therefore, combing both serological and molecular techniques increases the specificity and sensitivity of the testing method.
Several studies have indicated that detection of HEV RNA is needed to confirm persistent infection in blood and organ donation [81] [82] [83] . In particular in immunosuppressed individuals, HEV RNA quantification is currently considered the gold standard for confirming persistent infection [84, 85] . Yet, screening of blood products prior to blood donation/transfusion for the presence of HEV RNA remains controversial, especially in endemic areas, and it provokes ongoing debate for reasons mentioned previously [78, 86] . Persistent HEV infection has been identified in blood donors in Japan and China through the detection of HEV RNA, with an incidence of 0.014-0.020 % [87] [88] [89] . Moreover, analysis of European plasma has also identified HEV viraemic donors in France, Sweden, Germany, Spain, the Netherlands, England, Scotland and Austria [40, 82, 83, [90] [91] [92] [93] [94] [95] [96] [97] . In the UK, universal screening for HEV RNA is now accepted [35] .
Polymerase chain reaction (PCR)
Molecular diagnostic techniques are frequently used in evaluating the individual's health at the molecular level. Nucleic acid tests (NAT) are used as an alternative system for genome detection [97] . The PCR technique has revolutionized the field of molecular biology, because the enzymatic amplification of DNA can be performed even with small amounts of material [98] . Conventional PCR is the standard PCR protocol used to detect specific nucleic acid sequences by amplifying low-copy number DNA or RNA into several million folds [99] [100] [101] . Due to slight modifications of conventional PCR in detecting the desired gene sequence, different types of PCR have been introduced including real-time PCR, multiplex PCR and nested PCR (Table 2 ). These assays are highly sensitive, and their detection potential can reach 10-100 copies of the target RNA/DNA in a sample [102] . However, conventional PCR procedures take a long time before the results are yielded and a final diagnosis of HEV infection is made. Due to this limitation, the use of real-time PCR is considered to be a better option for early diagnosis of HEV in both epidemic and sporadic cases [103, 104] .
Real-time PCR
Real-time PCR has been introduced as a new method for molecular diagnosis. It has the same principle as conventional PCR, yet with higher specificity and sensitivity [105] . It allows data collection in the exponential growth phase of PCR, thus allowing measurement and quantification of the Outer primers:
Forward: 5¢-TGGCATCACTACTGCTATTGAG-3¢
Reverse: 5¢-CCGTCGAGGCAGTAAGGTGCGGTC-3¢
Inner primers:
Forward: 5¢-CTGCCCTGGCGAATGCT-3¢
Reverse: 5¢-AGCAGTATACCAGCGCTGAACATC-3¢
Outer primers: [144] Forward: 5¢-CCGAATTCAAAGGCATCCATGGTGTTTGAGAATGAC-3¢
Reverse: 5¢-CCGGATCCACACACATCTGAGCTACATTCGTGAGCT-3¢
Forward: 5¢-GGAATTCACAGCCGGCGATCAGGACAG-3¢
Reverse: 5¢-GGAATTCGACTCCACCCAGAATAACTT-3¢
Set one primer: [145] Outer primers:
Forward: 5¢-AAT(C)TATGCC(A)CAGTACCGGGTTG-3¢
Reverse: 5¢-CCCTTATCCTGCTGAGCATTCTC-3¢
Forward: 5¢-GTT(C)ATGC(T)TT(C)TGCATACATGGCT-3¢
Reverse: 5¢-AGCCGACGAAATC(T)AATTCTGTC-3¢ Set two primers:
Outer primers:
Forward: 5¢-GCCGAGTAT(C)GACCAGTCCACTTA-3¢
Reverse: 5¢-AT(C)AACTCCCGAGTTTTACCCACC-3¢
Forward: 5¢-TGGTT(G)AATGTT(A)GCGACC(T)GGCGCG-3¢
Reverse: 5¢-GCTCAGCGACAGTA(T)GACTGG(A)AAA-3¢
Outer primers: [146] Forward: 5¢-GCTATTATGGAGGAGTGT-3¢
Reverse: 5¢-CAGGGCCCCAATTCT-3¢
Forward: 5¢-GCGTGGATCTTGCAG-3¢
Reverse: 5¢-TTCAACTTCAAGCCACAG-3¢
Outer primers: [45] Forward: 5¢-CTGTTTAAYCTTGCTGACAC-3¢
Reverse: 5¢-WGARAGCCAAAGCACATC-3¢
Inner primer:
Forward: 5¢-GACAGAATTGATTTCGTCG-3¢
Reverse: 5¢-TGTTGGTTRTCATAATCCTG-3¢ or 5¢-TGCTGGTTATCGTAATCCTG-3¢
RT-PCR Forward: 5¢-TTCAACTTCAAG(A)CCACAGCC-3¢ [147] Reverse: 5¢-GCGTGGATCT(C)TGCAGGCC-3¢
Forward: 5¢-GTYATGYTYTGCATACATGGCT-3¢ [56] Reverse: 5¢-AGCCGACGAAATYAATTCTGTC-3¢
Forward: 5¢-ACTCTAGATTCAACGGCGCAGCCCCAGCT-3¢ [46] Reverse: 5¢-GCTAGCCACCATGGGATCACCATGCGCCCT-3¢
Real-time PCR
Forward: 5¢-CGGTGGTTTCTGGGGTGA-3¢ [148] Reverse: 5¢-GCRAAGGGRTTGGTTGG-3¢
Probe: 5¢-FAM-ATTCTCAGCCCTTCGC-MGB-3¢
Forward: 5¢-GGTGGTTTCTGGGGTGAC-3¢ [84] Reverse: 5¢-AGGGGTTGGTTGGATGAA-3¢
Probe: 5¢-FAM-TGATTCTCAGCCCTTCGCBBQ-3¢
Forward: 5¢-GGTGGTTTCTGGGGTGAC-3¢ [39] product by the end of each cycle [106] . Compared to conventional PCR, real-time PCR minimizes cross-contamination between samples and expedites the analysis [107, 108] . RNA detection is considered the gold standard for HEV diagnosis, and is broadly applied as a sole method for the identification of HEV genotypes or sub-genotypes. The HEV RNA genome contains some conserved sequences that can be targeted for amplification by PCR and detected either conventionally by gel electrophoresis or by fluorescent detection using real-time PCR.
Different molecular assays and commercial kits have been developed for HEV RNA detection, though they are variable in sensitivity and specificity. For instance, Roche has a product intended for the quantification of HEV viral load (LightMix HEV) and another product is currently under development (COBAS HEV). Mikrogen Diagnostik produces a system for the quantification of HEV RNA by real-time PCR (AmpliCube HEV 2.0 kit). Ceeram, La Chapelle sur Erdre also produces a kit for HEV RNA quantification (hepatitis@ceeramTools kit). However, bioM erieux announced the acquisition of Ceeram whereby ceeramTools detection kits will expand bioM erieux food testing portfolios [109] . According to our understanding, Ceeram kit production is temporarily suspended. In this review, this kit will be referred to as Ceeram kit. Finally, Altona Diagnostics produces a qualitative virus RNA detection system (RealStar HEV RT-PCR 1.0 kit). Most RT-PCR assays target a conserved region of the HEV genome for laboratory diagnosis, keeping in consideration the wide HEV genetic heterogeneity. Therefore, primers and probes designed for HEV RNA should be highly sensitive and specific [110] .
The AmpliCube HEV 2.0 kit uses the RT-PCR technique to detect HEV RNA in human plasma or serum. A study conducted in Portugal used two commercial real-time RT-PCR kits (AmpliCube HEV 2.0 kit and RealStar HEV RT-PCR 1.0) to detect HEV RNA [111] . Out of a total of 2115 blood donors, 19 (0.90 %) tested positive for HEV RNA. The AmpliCube HEV 2.0 kit has both high sensitivity and specificity when using high sample concentration. For instance, it showed 100 % sensitivity when the sample concentration was 400 IU ml -1 [38] . However, when the sample concentration decreased to 200 IU/ml, sensitivity dropped to 91.7 % while other kits (e.g. RealStar HEV RT-PCR 1.0 kit and Ceeram kit) showed 100 % sensitivity with a sample concentration of 200 IU ml
À1
. To summarize despite the presence of minor variability in the analytical sensitivity of different kits, all RT-PCR assays used in this study showed an equally good sensitivity for HEV detection [38] .
Another molecular kit that is based on real-time PCR technique is RealStar HEV RT-PCR 1.0. In order to ensure high analytical specificity of the RealStar HEV RT-PCR 1.0 kit, specific oligonucleotides were selected and checked against published sequences. This approach ensures that only HEV genotypes will be detected [112] . Moreover, the kit specificity was evaluated using a genomic panel of DNA/RNA molecules extracted from related viruses that produce symptoms similar to HEV. The RealStar HEV RT-PCR 1.0 kit is commonly reported in the literature. For instance, a study conducted in Germany aimed at examining the seroprevalence of HEV in blood donors to assess the risk of transfusion-transmitted HEV [113] . HEV nucleic acid was detected using the RealStar HEV RT-PCR 1.0 kit, and 3 of 7 (42.8 %) donors' samples tested positive. In another study, Abravanel and colleagues assessed the performance of two commercial HEV RNA assays, RealStar HEV RT-PCR 1.0 and Ceeram kit [56] . This was achieved by testing the ability of the kits to detect HEV RNA, particularly HEV-3. Serial dilution of the HEV RNA World Health Organization (WHO) international standard was used as reference. This standard has HEV genotype 3a, 3c, 3e and 3f strains. Both kits were effective in detecting all samples at 2500 and 500 IU ml -1 concentrations [56] . When the sample concentration was titrated down to 100 IU ml -1 , Table 2 . cont.
Method Primers Reference
Reverse: 5¢-AGGGGTTGGTTGGATGAA-3¢
Probe: 5¢-TGATTCTCAGCCCTTCGC-3¢
Forward: 5¢-CGGTGGTTTCTGGGGTGA-3¢ [149] Reverse: 5¢-GCRAAGGGRTTGGTTGG-3¢
Probe: 5¢-FAM-ATTCTCAGCCCTTCGC-MGB-3¢ ORF2 [150] Forward: 5¢-GACAGAATTRATTTCGTCGGCTGG-3¢
Reverse: 5¢-CCCTTRTCCTGCTGNGCATTCTCGACAGA-3¢
Probe: 5¢-FAM-GTYGTCTCRGCCAATGGCGAGCTAMRA-3¢
ORF3
Forward: 5¢-GGTGGTTTCTGGGGTGAC-3¢
Probe: 5¢-FAM-TGATTCTCAGCCCTTCGC-TAMRA-3¢
Forward: 5¢-CGGTGGTTTCTGGGGTGA-3¢ [96] Reverse: 5¢-GCRAAGGGRTTGGTTGG-3¢
Probe for Ceeram kit [112] . Therefore, RealStar HEV RT-PCR 1.0 has higher sensitivity than the Ceeram kit. This was also supported by a study performed by Baylis and colleagues, who demonstrated that the RealStar HEV RT-PCR 1.0 kit displayed a 10-fold higher analytical sensitivity, while Ceeram kit and AmpliCube HEV 2.0 showed lower analytical sensitivity [114] . Moreover, these three kits were assessed by screening individual samples. It was demonstrated that RealStar HEV RT-PCR 1.0 consistently had the highest sensitivity (detection limit up to 37.8 IU ml Abravanel and colleagues attributed the differential sensitivity of these kits to differences in RNA input volumes when each assay was designed [56] . For instance, RealStar HEV RT-PCR 1.0, AmpliCube HEV 2.0 and Ceeram kit recommend the use of 25, 20 and 5 µl RNA, respectively. A prior assessment of the kits revealed a 100-1000-fold difference in their sensitivities, regardless of virus strain [115] . In this study, 20 different laboratories worldwide were asked to test a panel of 22 HEV positive plasma samples obtained from blood donors using their routine assays. Although all laboratories used conventional or real-time PCR techniques, one of the laboratories reported all HEV-positive samples as negative. Another lab detected all HEV-positive samples except for the most diluted samples. Differences in analytical sensitivity were attributed to the use of different primers that may not target a conserved region of the HEV genome. Moreover, some assays were designed to detect specific HEV ORFs. For instance, nested PCR used in this study targeted only HEV ORF1. To summarize, although NAT techniques are preferred for HEV detection and infection confirmation, there are some differences in their sensitivities. Therefore, it would be valuable to develop a standardized NAT assay for HEV RNA detection.
Loop-mediated isothermal amplification assay
Another technique used for the detection of HEV RNA is loop-mediated isothermal amplification assay (LAMP). Similar to real time-PCR, no further downstream techniques are required in LAMP. However, unlike the PCR technique, LAMP involves isothermal amplification, between 60 and 65 C [116] . In this technique, a set of six different primers are used to recognize six distinct sequences in the target DNA/RNA and then form stem-loop structures [117, 118] . The result is an accumulation of double-stranded DNA and amplification byproducts. Throughout the process, magnesium ions will bind to pyrophosphate ions that were produced in the amplification reaction. This binding will result in the formation of white precipitate, and hence interpretation of the reaction result by measuring the sample turbidity [116, 119] . This method could have high sensitivity and efficiency. For instance, a study examined 68 specimens using both LAMP and nested PCR techniques. Both assays established high specificity. However, LAMP reaction was significantly faster in detecting and amplifying HEV sequence than nested PCR [120] . Moreover, this study showed that the LAMP detection limit was nine copies/reaction, while the nested PCR detection limit was 900 copies/ reaction. Therefore, the LAMP technique had 100-fold higher sensitivity than nested PCR and fairly good specificity [120] . In a total of 68 samples, RT-LAMP assay detected 44 HEV-negative samples and 24 HEV-positive samples. On the other hand, nested PCR assay detected 48 HEV-negative samples and 20 HEV-positive samples. Therefore the sensitivities of RT-LAMP and nested PCR assays were 100 and 92 %, respectively.
Transcription-mediated amplification
Infectious pathogens can be identified based on their sequences and quantified using transcription-mediated amplification (TMA). This technique is specific, sensitive and rapid, yet highly versatile [121] . It is isothermal and based on biochemical reactions for the amplification rather than mechanical thermo-cycling. TMA involves three main phases, all of which take place in a single tube in a fully automated Panther System [122] . For more details of the TMA detection method, please visit the following site: http://www.procleix.com/en/web/procleix/tma-technology. Amplification will result in multiple copies of RNA amplicon that can be detected by fluorescent-labelled probes. These probes will bind to the RNA amplicons during the exponential amplification phase. As more amplicons are generated, more probes bind and progressively higher fluorescent signals are generated. This technology offers accurate, precise and sensitive identification and quantification of infectious pathogens [121] .
The Procleix HEV assay is based on the TMA assay, and the specificity varies from 99.96 to 99.99 % [97, 123] . For instance, a study conducted in Catalan (Spain) aimed at assessing the prevalence of HEV RNA in blood donors [97] . A total of 9998 samples were analysed using Procleix HEV assay. Four samples were reactive, and hence considered positive. However, one of these samples was negative upon retesting using the same kit, and thus considered a falsepositive sample. The specificity of Procleix HEV assay, based on the results, is determined to be 99.99 %, which supports previously reported studies. The three HEV-positive samples were confirmed using in-house real-time quantitative PCR assay. The study concluded that HEV RNA prevalence in Catalan blood donors is 0.03 % [97] . Another study aimed at investigating HEV genotypes and assessing the levels of HEV RNA present in plasma pools. A total of 484 manufacturing plasma pools from Europe, North America, Asia and the Middle East were screened using TMA assay and then confirmed by real-time PCR. Initial screening revealed 43 % HEV-positive samples in Asian pools. However, this percentage dropped to 25 % upon using real-time PCR as a confirmatory test. Likewise, North American pools had about 10 % HEV-positive samples, which dropped to 3 % after real-time PCR confirmatory testing. This decrease in HEV-reactive pools after using real-time PCR confirmatory testing could be due to the sensitivity and detection limit differences between Procleix HEV assay and real-time PCR. Procleix HEV assay and real-time PCR confirmatory test had detection limits of 7.8 and 64 IU HEV RNA/ml, respectively [124] . In addition, other studies conducted in Ireland and Australia aimed at determining the prevalence of HEV RNA in the sera of blood donors [125, 126] . To this end, 24 985 and 14 799 samples from Ireland and Australia, respectively, were examined using the Procleix TMA HEV assay. Results showed that five samples tested positive for HEV RNA in the Irish-donated blood samples while only one sample was positive for HEV RNA in the Australian-donated blood samples. Reactive samples were confirmed by an in-house real-time PCR test.
All HEV RNA detection methods are particularly important for HEV detection in serum samples, especially for screening HEV in blood donors. Noteworthy, none of the previously discussed assays are FDA-approved for the diagnosis of HEV from human samples. However, in Europe, these kits passed the technical standard requirements by CE (Conformit e Europ eene) marker designation for marketing within the European Economic Area (EEA) as diagnostic tests for human samples [127, 128] .
HEV RNA sequencing Although real-time PCR is a sensitive tool for detecting HEV genome, it may not be suitable for typing and molecular characterization [129] . Genotyping of HEV RNA is usually achieved by reverse transcription of the HEV RNA, followed by nested-PCR of specific region and Sanger sequencing of the amplified genome target. It is widely accepted that HEV genotyping can be accomplished by Sanger sequencing of ORF2 (145 bp) and ORF1 (364 bp) PCR products [130] . However a clear consensus classification for HEV does not yet exist [131] . That is, according to phylogenetic studies, the homology percentage in members of the same HEV genotype is only about 75 % [132] . HEV genotypes 1 and 2 were divided into 5 and 2 subtypes, respectively, whereas genotype 3 was divided into 10 subtypes and 4 was divided into 7 subtypes. Furthermore, nested-PCR and sequencing can be also affected by the type of primers used, the targeted genome sequence and the quality of the sequencing. For instance, La Rosa et al. performed a comparative study to evaluate the sensitivity of nested-PCR assays in comparison to RT-PCR, using five different primer pairs (targeting ORF1, ORF2 and the ORF2/ORF3 overlapping region) in confirmed positive HEV samples [129] . Results revealed that only 46 % of samples tested positive by nested PCR and no single method detected all positive samples. These results demonstrate that RT-PCR is more sensitive than nested-PCR, which usually requires Sanger sequencing. That is, sequencing is important to both confirm and exclude any false-positive result. Finally, it can be concluded that although HEV RNA detection by conventional nested-PCR and sequencing is important for genotyping and possibly diagnosis, there are variabilities in assay sensitivity and lack of standardization [115] .
HEV MISDIAGNOSIS AND CHALLENGING CASES IN HEV DETECTION
HEV detection can be challenging, where some cases could have a low viraemia rate and unusual presentation. For instance, the first HEV transmission through blood transfusion was reported in 2004 in Japan [32] . HEV infection was revealed after transfusing 23 blood products infected with HEV RNA. In the UK, HEV was detected in pooled plasma products. However, the rate of HEV transmission by blood transfusion and its consequences remain unclear. A study conducted in the UK reported the prevalence of HEV RNA in blood donors and its transmission through a range of components [40] . A total of 225 000 donated blood samples were collected between October 2012 and September 2013 and screened for HEV RNA. Although all donors were seronegative, recipients of any blood component from these donations were identified and followed up for further analysis. It was found that 79 donors were viraemic with HEV-3, and 129 blood components were prepared from these viraemic donations. HEV antibodies were undetectable. Out of the 129 prepared blood components, 62 were transfused before identifying the infected donations. Follow-up examination revealed that 42 % of the recipients had signs of HEV infection. Later, 10 recipients developed prolonged HEV infection and 3 recipients cleared long-standing HEV infection after ribavirin treatment [40] . Another case was reported in the UK in which HEV was transmitted through blood transfusion from an asymptomatic blood donor [28] . Later, acute infection symptoms appeared in the donor and the diagnosis led to further investigation of HEV infection in the recipients. Similarly, a study was designed to determine HEV seroprevalence among pregnant women. A total of 116 asymptomatic pregnant women were involved in the study, and surprisingly, 68 (58.6 %) participants were HEVpositive [133] .
HEV detection is largely ambiguous since there are no wellestablished diagnostic standards. Laboratory findings and clinical symptoms related to HEV infection are vague and common among other hepatitis infections. Moreover, the use of HEV-antibodies diagnostic tests of low specificity and sensitivity has made HEV diagnosis somewhat difficult and challenging. Indeed, a recent study revealed that HEV IgM could potentially cross-react with other viruses including Epstein-Barr virus (EBV) (33.3 %) and cytomegalovirus (CMV) (24.2 %) [134] . Clearly, the lack of proper and standardized HEV detection assays would result in higher HEV infection rates in most blood transfusion cases.
Conclusions
Serological and molecular detection methods have been developed to detect HEV infection. This is achieved by detecting HEV antigens, HEV antibody or RNA in patients' sera. Each technique has advantages and disadvantages compared to other techniques. Yet, detection of HEV RNA remains the gold standard method. HEV seroprevalence in some countries is still obscure, since available serological assays used for detecting and quantifying HEV antibodies show discrepancies due to marked differences in specificity and sensitivity. Consequently, this has obscured the rate of viraemia in public surveillance studies. The combination of serological and molecular methods would result in higher sensitivity and specificity, and thus early detection of HEV and accurate diagnosis of HEV infection.
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